AF-HPA is an auristatin cargo used in the Dolaflexin platform. It can convert to active auristatin F, which has less access across membranes.
The Dolaflexin preclinical studies distinguish membrane-accessible auristatin F-hydroxypropylamide, or AF-HPA, from its less membrane-accessible but still active auristatin F metabolite. Auristatin F is not the same chemical as monomethyl auristatin F.
The XMT-1536 preclinical report describes roughly 10 to 15 AF-HPA molecules per antibody. This is a preparation-specific report, rather than a fixed mean or a common loading of eight. The earlier polyacetal Fleximer study used a vinca derivative; its platform name must not be treated as evidence for Dolaflexin composition. Cell and animal activity does not establish patient benefit or complete payload confinement.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
AF-HPA · How it is released · from an experiment
Membrane-accessible AF-HPA can convert to the less membrane-accessible but active auristatin F species.
Where: Dolaflexin preclinical conjugate and metabolite studies. How: Cell and animal characterisation.
Auristatin F is distinct from MMAF; the conversion does not establish complete confinement or human safety.
Checked 2026-11-09.
AF-HPA · Drug molecules per antibody · from an experiment
The preclinical report describes approximately 10 to 15 AF-HPA molecules per antibody; no fixed mean is inferred from that range.
Product: XMT-1536
Where: The named XMT-1536 product or preparation described by the source. How: Composition reported for the preclinical conjugate preparation.
This report does not assign a loading constant to every construct carrying this cargo or infer a patient dose.
Checked 2026-11-09.
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Drug efflux pumps (ABC transporters), Next-generation antibody-conjugate payloads.
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Drug efflux pumps (ABC transporters), Payload (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Drug efflux pumps (ABC transporters), Payload (ADC).
Shares Bystander effect (ADC), Drug efflux pumps (ABC transporters), Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/